AzTrials
AzTrials

Acetabular DysplasiaNCT03541122

Three Novel Radiological Indicators for Diagnosis of Adult Acetabular Dysplasia

An observational study of Acetabular Dysplasia, run by Hebei Medical University Third Hospital at 1 site in China.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Acetabular dysplasia often accompanies by acetabular bone hyperplasia and osteonecrosis of the femoral head. These pathological changes can alter the position of the center of the femoral head. Read more about this study

Who is it for?
Ages 16 years and older
Conditions the study is for
Acetabular Dysplasia
What is being tested?
pelvic X-ray examinations
How many people
200 participants
Where
1 siteChina
Study dates
1 Feb 2018to Dec 2019
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 16 years and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Potential patients will be informed of the study details through an announcement issued through the bulletin board of the Third Hospital of Hebei Medical University. Interested patients will directly contact the principle investigator via telephone, and among them, eligible patients will be required to provide written consent prior to the participation in the trial.

Who may be able to join

  • No experience in hip replacement, pelvic fixation or external fixation, and proximal femoral surgery;
  • No marked pelvic tilt;
  • No hip dislocation;
  • No obvious hip deformity, such as significant collapse of the femoral head and severe hip traumatic arthritis;
  • No significant lesions in the pelvis or proximal femur;
  • Aged over 16 years;
  • Provision of written informed consent.

Who cannot join

  • Those with advanced osteoarthritis;
  • Those with osteoarthritis secondary to acetabular dysplasia;
  • Those with ankylosing spondylitis involving the hip joint;
  • Those with rheumatoid arthritis;
  • Those with inflammatory inflammation of the hip joint;
  • Those with tumor lesions in the hip joint.

Trial locations and contacts

1 site in 1 country.

China1 site
  • Third Hospital of Hebei Medical University

    Shijiazhuang, Hebei, 050051

Other trials in China

About this study

Official title: Three Novel Radiological Indicators for Diagnosis of Adult Acetabular Dysplasia: a Self-controlled, Diagnostic Trial

Acetabular dysplasia often accompanies by acetabular bone hyperplasia and osteonecrosis of the femoral head. These pathological changes can alter the position of the center of the femoral head. Thus, measurement errors will be generated on the anteroposterior radiographs of the adult pelvis involving centre-edge angle, acetabular angle (Sharp angle), and acetabular head index, eventually resulting in the inaccurate diagnosis of acetabular dysplasia. Herein, the investigators describe the protocol to verify three novel X-ray indicators, including offshoring index (OFI), moving up index (MUI) and teardrop baseline offshoring index (TBOI) of the femoral head. All data will be expressed as relative ratios, as the investigators expect to make an accurate diagnosis through avoiding the generation of errors resulting from measurement angles.

Read the detailed description

Acetabular dysplasia is a developmental malformation of the hip joint where the acetabulum become shallow and cannot fully cover the femoral head and the centre of the hip joint moves outward, resulting in an increased risk for joint subluxation or dislocation.

Current diagnosis of acetabular dysplasia mainly depends on the pelvic anteroposterior X-ray film to understand whether there is dislocation of the hip joint, whether the concentricity of the femoral head and acetabulum is consistent, and whether there is secondary osteoarthritis or other hip diseases, such as femoral head ischemic necrosis, hip joint tuberculosis, and rheumatoid arthritis. The commonly used measurement indicators include centre-edge (CE) angle, acetabular angle (Sharp angle), and acetabular head index (AHI). Moreover, some differences exist in the measurement results between male and female patients. Acetabular dysplasia often accompanies by acetabular bone hyperplasia and necrosis of the femoral head, which have a greater impact on radiographic measurements, especially when measured with angles. It is difficult to determine the radiological landmark for the lateral edge of the acetabular roof due to the existence of bone hyperplasia, which produces a great influence on the accuracy of the measurement of the centre-edge angle and Sharp angle.

Being tested
pelvic X-ray examinations
Medical subject headings
Hip Dislocation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • pelvic X-ray examinationsDiagnostic test

    Measurement indicators will include OFI, MUI, TBOI, CE angle, Sharp angle and AHI of the affected and healthy femoral heads.

Study groups in NCT03541122
Study groupRoleWhat they receive
Experimental groupPatients will undergo pelvic X-ray examinations. Measurement indicators will include OFI, MUI, TBOI, CE angle, Sharp angle and AHI of the affected and healthy femoral heads. The investigators will determine the sensitivity and specificity of OFI, MUI and TBOI for the diagnosis of adult acetabular dysplasia, and compare the accuracy of diagnosis between these three indicators and CE angle, sharp angle, and AHI. Further analysis of risk factors for hip function will be implemented.
Receives: Diagnostic Test: pelvic X-ray examinations

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The sensitivity of offshoring index (OFI)

    The sensitivity represents the percentage of actual patients who are correctly diagnosed with a disease. A higher sensitivity indicates a higher rate of correct diagnosis for acetabular dysplasia.

    Measured: One day after hospitalization

Secondary outcomes (5)
  1. The specificity of OFI,MUI and TBOI

    The specificity represents the percentage of disease-free patients who are correctly diagnosed with no disease. A higher specificity indicates a higher rate of correct diagnosis for acetabular dysplasia.

    Measured: One day after hospitalization

  2. The positive predictive value of OFI,MUI and TBOI

    The positive predictive value represents the probability that the patient actually suffer from the disease (true positive rate) in all positive cases.

    Measured: One day after hospitalization

  3. The negative predictive value of OFI,MUI and TBOI

    The negative predictive value represents the probability that the patient does not suffer from have the disease. This value is often influenced by the sensitivity, specificity, and prevalence in all cases.

    Measured: One day after hospitalization

  4. The positive likelihood ratio of OFI,MUI and TBOI

    The positive likelihood ratio represents the probability of a patient who has the disease testing positive divided by the probability of a patient who does not have the disease testing positive.

    Measured: One day after hospitalization

  5. The negative likelihood ratio of OFI,MUI and TBOI

    The negative likelihood ratio represents the probability of a patient who has the disease testing negative divided by the probability of a patient who does not have the disease testing negative.

    Measured: One day after hospitalization

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 May 2018
  2. Study start1 Feb 2018
  3. Primary completionOct 2019 (estimated)
  4. Study completionDec 2019 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Prospective
Enrolment
200 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03541122
Sponsor's protocol ID
HebeiMUth-003
Status last verified
May 2018
First submitted
17 May 2018
Last updated
30 May 2018
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Acetabular Dysplasia, run by Hebei Medical University Third Hospital at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 30 May 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The sensitivity of offshoring index (OFI) (time frame: One day after hospitalization). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 May 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in